The groundbreaking success of Sildenafil undeniably reshaped the medication landscape, but betting in companies heavily reliant on off-patent versions presents a uncertain picture. While early earnings were significant, the cessation of patents and the appearance of discounted alternatives have eroded sales. Consequently, a thorough analysis of cur